摘要
目的 多发性骨髓瘤（mutciple myelome,MM）是血液系统恶性肿瘤,近年来,MM的治疗已经取得了显著的进展.一些新药沙利度胺、硼替佐米、雷利度胺的应用扩大了MM患者的治疗选择并改善了预后.大量的Ⅲ期临床实验已经表明了新药联合治疗移植和非移植患者的有效性,基于这些研究结果,标准的诱导方案已经受到挑战、甚至被取代.对于适合移植的患者,一些新的诱导缓解方案的有效性优于长春新碱＋多柔比星＋地塞米松（VAD）方案.同样,对于不适合移植的患者,联合这些新药的一线治疗也被证明优于传统的马法兰＋泼尼松（MP）方案.现基于新药的联合治疗策略就MM的治疗进展进行综述.
Multiple myeloma（MM） is a hematological malignancy. The treatment of multiple myeloma has undergone significant developments in recent years. The availability of the novel agents induding thalidomide, bortezomib, and lenalidomide has expanded treatment options and improved the outcome of patients with MM. A number of phase III trials have demonstrated the efficacy of novel agent combinations in the transplant and nontrans- plant settings. Based on these results, standard induction regimens are being challenged and replaced. In the trans- plant setting, a number of newer induction regimens are now available. It has been shown to be superior to the vincristine, doxorubicin, and dexamethasone （VAD）regimen. Similarly, in the front -line treatment of patients not eligible for transplantation, regimens incorporating novel agents have been found to be superior to the traditional melphalan plus prednisone（MP） regimen. The advance of therapy of multiple myeloma based on the combination of the novel agents treatment strategies are reviewed.
出处
《实用肿瘤学杂志》
CAS
2012年第2期183-187,共5页
Practical Oncology Journal
